Product Details
VILDAGLIPTIN 50 MG + DAPAGLIFLOZIN 5 MG
Introduction : This combination of VILDAGLIPTIN 50 MG + DAPAGLIFLOZIN 5 MG medication is indicated for the treatment of type 2 diabetes mellitus (T2DM) in adults to improve glycemic control when diet and exercise alone are not sufficient.
It is particularly useful for patients who require dual therapy with both a DPP-4 inhibitor (vildagliptin) and an SGLT2 inhibitor (dapagliflozin) to achieve target blood sugar levels.
Indication : The combination of Vildagliptin 50 mg + Dapagliflozin 5 mg tablet is primarily used for the treatment of type 2 diabetes mellitus (T2DM) in adults.
Improving Glycemic Control: Vildagliptin 50 mg + Dapagliflozin 5 mg tablet is particularly beneficial for patients with T2DM who have not achieved adequate glycemic control with diet and exercise alone or with other antidiabetic medications. It helps regulate blood sugar levels and reduces the risk of hyperglycemia.
Preventing Complications: By effectively managing blood sugar levels, Vildagliptin SR + Dapagliflozin helps reduce the risk of diabetes-related complications such as cardiovascular disease, kidney disease, neuropathy, and retinopathy.
Administration : The dosage of Vildagliptin 50 mg + Dapagliflozin 5 mg tablet may vary depending on individual patient factors and glycemic control goals.
It is typically taken orally once daily with or without food, as directed by a healthcare professional.
While taking the extended-release tablet, part of the tablet may pass into your stool after your body has absorbed the medicine. This is normal and nothing to worry about.
Storage : Store the medication at room temperature, away from moisture, heat, and direct sunlight.
Mechanism of Action : Vildagliptin inhibits the enzyme DPP-4, which leads to increased levels of active incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). These hormones stimulate insulin secretion and inhibit glucagon release in a glucose-dependent manner, thereby improving glycemic control.
Dapagliflozin inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion. This mechanism of action promotes the elimination of excess glucose from the body, leading to reduced blood sugar levels.
Therapeutic : Antidiabetic
Side Effects : Hypoglycemia (especially when used in combination with insulin or insulin secretagogues)
Genital yeast infections or urinary tract infections
Increased urination or thirst
Nasopharyngitis (common cold)
Headache
Dizziness
Safety Advice / Warnings : Patients should be monitored regularly for signs of hypoglycemia, especially when Vildagliptin 50 mg + Dapagliflozin 5 mg tablet is used in combination with insulin or insulin secretagogues.
This medication should be used with caution in patients with renal impairment, as dapagliflozin is primarily excreted by the kidneys, and dose adjustments may be necessary to prevent adverse effects
.
Vildagliptin SR + Dapagliflozin should not be used in patients with type 1 diabetes mellitus or diabetic ketoacidosis.
Patients should be advised to adhere to a regular meal schedule and monitor blood sugar levels closely while taking this medication.
References : Product Information: Jalra oral tablets, vildagliptin oral tablets. Novartis Europharm Limited (per EMA), Camberley, United Kingdom, 2015.
Product Information: Galvus oral tablets, vildagliptin oral tablets. Novartis Europharm Limited (per EMA), Camberley, United Kingdom, 2016.
Scheen AJ, Tan MH, Betteridge DJ, et al. Long-term glycaemic efficacy and weight changes with dapagliflozin versus sitagliptin add-on in inadequately controlled type 2 diabetes on metformin
"Product Information: FORXIGA(R) oral tablets, dapagliflozin oral tablets. AstraZeneca Pharmaceuticals LP (per manufacturer), Wilmington, DE, 2021.
Dandona P, Mathieu C, Phillip M, et al: Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5(11):864-876."